December 9, 2014

0 Comments

Year End 2014

The Institute has been involved in very exciting work this year. We have identified new treatments for myeloma, identified new ways to follow the disease and completed research that has led to a better understanding of the biology of myeloma. First, we have found that a drug named Jakafi, that is used to treat a […]

Continue reading...

December 9, 2014

0 Comments

Tommy Garceau, IMBCR’s Marathon Team Captain

Tommy Garceau, IMBCR’s Marathon Team Captain

Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for athletics and training. In July 2013, he started Team IMBCR at a time when he was also participating in several marathons, half-marathons and trail running and half iron distance events. Team IMBCR later became an official charity of the 2014 […]

Continue reading...

June 23, 2014

0 Comments

ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM). This multicenter, single-arm phase 1/2 study (NCT01677858) is evaluating the safety and efficacy of once-weekly CFZ with dexamethasone (DEX). Methods: Patients (pts) with relapsed or refractory MM who received 1−3 […]

Continue reading...

June 18, 2014

0 Comments

An Overview of Progress in Myeloma Research with Dr. James Berenson

Myeloma news from the 2014 annual meeting of the American Society of Clinical Oncology has included updates on proteasome inhibitors, overcoming drug resistance, monoclonal antibodies and more. In this brief video, Dr. James Berenson, a leading myeloma researcher and physician, gives an overview with a focus on what’s important for patients today. Original Link

Continue reading...

April 25, 2014

0 Comments

Multiple Myeloma: ‘Old Rules’ No Longer Apply

Original Article Writen by: Robert Carlson – Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple myeloma have become plentiful in the past few years, with a panoply of options. Consequently, “the old rules no longer apply,” says James Berenson, MD, President and Chief Medical Officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., speaking […]

Continue reading...

April 10, 2014

0 Comments

Counterpoints: To Transplant or Not To Transplant

More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is the most common primary malignancy of the bone marrow.1, The 5-year survival rate for MM patients has increased from 25% in 1975 to almost 40% due to newer and more effective drugs, such as the immunomodulatory agents (IMiDs) thalidomide and […]

Continue reading...
Scroll Up